EOM Pharmaceutical Holdings, Inc. (IMUC)
(Delayed Data from OTC)
$0.16 USD
-0.09 (-35.48%)
Updated May 21, 2024 12:37 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
EOM Pharmaceutical Holdings, Inc. [IMUC]
Reports for Purchase
Showing records 21 - 40 ( 90 total )
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Major Overhang Removed as CIRM Steps Up in a Big Way; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Go Enjoy a Spa, They Got the SPA;Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The State of Immunotherapy 3.0: "Silver Linings Immunobook"; Bright Horizons
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2014 Results; Pivotal Year With Expected ICT-107 Phase III
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
SNO Update Continues to Point to Phase III Start; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 results; Anticipating SNO Update & ICT-140 Phase II Initiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Expands with Potential Disruptive T-Cell Therapy Approach
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
FDA Feedback, Upcoming Oral and a Planned Phase III; Great Visibility
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2Q14 Results; Important Regulatory and Clinical Updates Coming
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.